WO2008051561A2 - Appareil et proceédeé permettant d'administrer un agent d'etancheéiteé biologique - Google Patents

Appareil et proceédeé permettant d'administrer un agent d'etancheéiteé biologique Download PDF

Info

Publication number
WO2008051561A2
WO2008051561A2 PCT/US2007/022533 US2007022533W WO2008051561A2 WO 2008051561 A2 WO2008051561 A2 WO 2008051561A2 US 2007022533 W US2007022533 W US 2007022533W WO 2008051561 A2 WO2008051561 A2 WO 2008051561A2
Authority
WO
WIPO (PCT)
Prior art keywords
adaptor
toothed
housing
cylinder
cartridge
Prior art date
Application number
PCT/US2007/022533
Other languages
English (en)
Other versions
WO2008051561A3 (fr
Inventor
John L. Wheeler
Gary Whipple
A. David Boccuti
Thomas T. Washburn
Andrew Nicholas Gentil
J. Brent Ratz
John Spiridigliozzi
Original Assignee
Spinal Restoration, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spinal Restoration, Inc. filed Critical Spinal Restoration, Inc.
Publication of WO2008051561A2 publication Critical patent/WO2008051561A2/fr
Publication of WO2008051561A3 publication Critical patent/WO2008051561A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00491—Surgical glue applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00491—Surgical glue applicators
    • A61B2017/00495—Surgical glue applicators for two-component glue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A61M2005/3152—Piston or piston-rod constructions, e.g. connection of piston with piston-rod including gearings to multiply or attenuate the piston displacing force
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31566—Means improving security or handling thereof
    • A61M5/31573—Accuracy improving means
    • A61M5/31575—Accuracy improving means using scaling up or down transmissions, e.g. gearbox
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
    • A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31593—Multi-dose, i.e. individually set dose repeatedly administered from the same medicament reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/48—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for varying, regulating, indicating or limiting injection pressure
    • A61M5/486—Indicating injection pressure

Definitions

  • the disclosure herein generally relates to an apparatus and method for the delivery of a biologic sealant such as fibrin sealant.
  • Fibrin sealants and glues, are well known and are used extensively in various clinical settings. Such sealants are indicated as adjuncts to hemostasis in surgeries when control of bleeding by conventional surgical techniques, including suture, ligature, and cautery is ineffective or impractical. In these cases, the sealant was applied topically. Delivery devices have been developed for these uses. Typical fibrin sealant devices are adapted to spray the fibrin sealant.
  • This invention provides a solution to one or more of the disadvantages and desired capabilities described above.
  • a biologic sealant such as fibrin sealant can be introduced into, for example, the spinal area of a human being.
  • Fibrin sealant comprises fibrinogen and thrombin, which form fibrin when mixed.
  • Calcium chloride may be included in the fibrin sealant.
  • the fibrin may optionally include one or more additives, such as various biological and non- biological agents.
  • this invention is an apparatus for delivery of a biologic sealant.
  • This device comprises a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for a fluid, a plunger within each cylinder for pushing the fluids out of the cylinder, a housing adapted to receive the cartridge, wherein the housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, a trigger connected to the housing, wherein the trigger includes a toothed drive rack, a toothed wheel assembly that cooperates with the toothed drive rack and with the toothed rams.
  • this invention is a method of making a device for delivery of biologic materials, comprising: providing a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for a fluid, providing a plunger within each cylinder for pushing the fluids out of the cylinder, providing a housing adapted to receive the cartridge, wherein the housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, providing at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, providing a trigger connected to the housing, wherein the trigger includes a toothed drive rack, providing a toothed wheel assembly that cooperates with the toothed drive rack and with the toothed rams.
  • this invention is a kit for treating a disc, comprising: fibrinogen, thrombin, and a device for delivery of biologic materials, wherein the device comprises: a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for a fluid, a plunger within each cylinder for pushing the fluids out of the cylinder, a housing adapted to receive the cartridge, wherein the housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, a trigger connected to the housing, wherein the trigger includes a toothed drive rack, a toothed wheel assembly that cooperates with the toothed drive rack and with the toothed rams.
  • this invention is a method of making a kit, comprising providing fibrinogen, providing thrombin, and providing a device for delivery of biologic materials, wherein the device comprises: a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for a fluid, a plunger within each cylinder for pushing the fluids out of the cylinder, a housing adapted to receive the cartridge, wherein the housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, a trigger connected to the housing, wherein the trigger includes a toothed drive rack, a toothed wheel assembly that cooperates with the toothed drive rack and with the toothed rams.
  • this invention is a method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus, comprising: injecting a fibrin sealant or other biologic sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinogen and thrombin, wherein the fibrin sealant is injected using a delivery device that comprises: a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for a fluid, a plunger within each cylinder for pushing the fluids out of the cylinder, a housing adapted to receive the cartridge, wherein %e housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, a trigger connected to the housing, wherein the trigger includes a toothe
  • the housing and the cartridge are together monolithic;
  • the cartridge is a separate component from the housing that is inserted into the housing;
  • the device includes a pressure monometer operably connected to measure the pressure in at least one cylinder; wherein the plungers are attached to the rams;
  • the wheel assembly includes an inner toothed wheel sandwiched between two outer toothed wheels each of smaller diameter than the inner wheel;
  • the drive rack engages the wheel assembly upon manual pressure to the trigger and wherein the drive rack disengages the wheel assembly upon release of pressure on the trigger, and falls away;
  • the device includes a fill manifold for introducing fluids into the cylinder, wherein the fill manifold comprises a fill manifold adaptor that couples to the adaptor of the delivery device wherein the adaptor includes at least two exit ports that each couple to the at least two exit ports of the housing adaptor, at least two syringes, at least two conduits wherein one end of the conduit connects to the syringe and a second
  • This invention also includes a kit including the delivery device of this invention and the components used to inject the fibrin sealant.
  • the components may comprise fibrinogen, such as freeze-dried fibrinogen, thrombin such as freeze-dried thrombin, and the delivery device.
  • the kit can optionally include CaCI, contrast agent and other additives.
  • the device, methods, and kit of this invention facilitate extended pain relief for patients with discogenic pain, wherein for example nucleus pulposus leaks out of the disc through defects (e.g. tears or fissures) in the annulus fibrosus.
  • nucleus pulposus leaks out of the disc through defects (e.g. tears or fissures) in the annulus fibrosus.
  • the device of this invention which employs an outer introducer needle and an inner needle within the introducer needle, wherein the tip of the inner needle does not protrude past the distal tip of the outer introducer needle, and in one embodiment is approximately one inch from the distal tip of the outer introducer needle, provides a final fibrin sealant clot with surprising properties.
  • This needle configuration facilitates mixing of the components of the fibrin sealant (or other biologic sealant) to provide improved set-up time (or "work time"), less viscosity with slower set up to afford easier use in practice and higher penetration of sealant into tears, fissures, and so forth, enhanced mechanical properties of the final sealant including greater elasticity (easier to deform) with slightly less failure load (i.e., the force required to make a permanent rupture), approximately a 200% improvement in fracture toughness (i.e., need twice as much energy to break the sealant as compared to a clot made using a standard device), extended solidification time of about twice as long to reach 10,000 poise viscosity, with the ultimate sealant having sufficient mechanical properties to be useful for intradiscal injections.
  • the device of this invention advantageously allows a practitioner to reuse the delivery gun in a sterile environment for multiple injections for a patient by removing the injection manifold, loading the cartridges with fresh sealant components, attaching the same or new injection manifold, inserting a second or the same introducer needle intradiscally, inserting the inner needle within the introducer needle, and applying pressure to the trigger to inject sealant.
  • the device should be primed with sealant components prior to insertion of the inner needle.
  • the device of this invention where the inner needle does not extend past the distal tip of the outer needle, and where the tip of the inner needle is within an inch or two inches from the distal tip of the longer outer needle, it has been found that partially set up sealant within the needles can be readily pushed out of the needles to thereby advantageously clear (unclog) the needles for delivery of additional sealant, which begins mixing at the tip of the inner needle.
  • FIG. 1 shows a semi-exploded view of one embodiment of the device of this invention.
  • FIG. 2 shows a semi-exploded view of components of one embodiment of the device of this invention.
  • FIG. 3 shows a device of this invention, including exit ports 38, 38' of the cartridge 30.
  • FIG. 4 shows a perspective view of the device of this invention.
  • FIG. 5 shows a wheel assembly used in one embodiment of the device of this invention.
  • FIGS. 6-8 show one embodiment of the needle assembly of this invention.
  • FIGS. 9A, 9B, and 9C show representative cross-sectional views of multi-lumen catheters.
  • FIG. 10 shows the device of this invention with a delivery manifold operably attached to the device.
  • FIG. 11 shows the device of this invention with a fill manifold operably attached to the device.
  • FIG. 12 shows the device of this invention from a cross-sectional view.
  • FIG. 13 shows a graph of dynamic setting viscosity profiles for fibrin delivered from a DUPLOJECT device and from a device of this invention.
  • the device of this invention comprises: a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for fluid, a plunger within each cylinder for pushing fluids out of the cylinder, a housing adapted to receive the cartridge, wherein the housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, a trigger connected to the housing, wherein the trigger includes a toothed drive rack, a toothed wheel assembly that cooperates with the toothed drive rack and with the toothed rams.
  • the device 10 includes a housing 20 that holds or is connected to some of the device's other parts.
  • the housing can be made from a variety of materials, but is typically made from one or more plastic materials.
  • the housing can generally be referred to as being in the shape of a pistol or gun, including a handle 21 and barrel 22.
  • a cartridge 30 is positioned within the barrel 22.
  • the housing is adapted to receive and house the cartridge.
  • the cartridge 30 is thus positioned within the barrel 22.
  • the housing can be a multi-piece component, such as a two piece housing that is assembled using screws, or configured using snap-in type functionality.
  • the specific design shown in FIG. 1 is merely representative and not intended to limit the types of housings employed in the practice of this invention.
  • a trigger 40 is operably connected to and situated within the housing so that the trigger 40 can slide from a first position into the housing to a second position as pressure is applied by the operator to the trigger 30.
  • the housing 20 can include an internal stop, not shown, for the travel of the trigger 30.
  • the cartridge 30 is depicted in greater detail in FIG. 2.
  • the cartridge 30 includes two cylinders 31 , 31' that each has a bore 32, 32" for receipt of a fluid.
  • Each cylinder 31 , 31 ' defines a generally straight tube having the same diameter for the length of the bores 32, 32'.
  • the cartridge 30 may include one or more fittings, slots, or the like that serve to secure the cartridge 30 within the housing. For example in FIG.
  • the housing includes a fitting 53 that is configured to fit within slot 37 of the cartridge to thereby secure cartridge 30 from lateral movement.
  • the cartridge 30 does not move upon application of pressure to the trigger 40. Rather, application of pressure to the trigger 40 engages the rack 42, wheel assembly 50, and rams 34, 34' to push the plungers 36, 36' toward the exit ports 38, 38' (see FIG. 3) of the cartridge 30.
  • the extended gear ends 51 , 51' of the wheel assembly 50 fit into bore 33 of the cartridge 30 (see also FIG. 4).
  • the cartridge 30 can be integral with the housing 20.
  • the cartridge 30 need not be a separate and/or detachable component that is placed within the housing but instead can be formed as part of the housing during fabrication of the housing. Likewise, the cartridge can be of one-piece or multi-piece construction. In the figures the cartridge 30 is one-piece.
  • the wheel assembly 50 can be a single piece or can be assembled from multiple parts to form the assembly.
  • a toothed internal gear 52 having extended gear ends 51 , 51' is inserted into internal bore 53 of wheel 50.
  • the gear 52 is adapted to engage the wheel 50, such as by interdigitating teeth, so that the assembly would move as a single part during use of the device 10.
  • the inner toothed gear 52 can be seen to be sandwiched between the extended gear ends 51 , 51.
  • the wheel assembly can be cast, forged, milled, or otherwise formed to manufacture a single monolithic wheel assembly.
  • the wheel assembly 50, rack 42, and rams can be made of materials that engage with sufficient friction to provide the desired movement, using for example tacky rubber materials, materials have a grainy surface (e.g., with a sand-paper like finish), and so on.
  • a pressure read-out display 60 that provides the surgeon with a pressure reading within one of the bores 32, 32 * of the cartridge 30.
  • a transducer is configured to measure pressure within a bore and a line, not shown, from the transducer to the display 70 provides a signal to electronic circuitry that processes the signal and provides a reading to display 70.
  • the pressure monitor couples to the delivery device through a line connected to a transducer in, for example, one of the syringes.
  • the transducer can be located within the connector, or anywhere else where the transducer can be introduced within the device such that pressure of within the device can be measured.
  • the transducer is in the bore.
  • the display can be but is not limited to an LCD.
  • Pressure monitors are available commercially.
  • a suitable pressure monitor is currently available from Merit Medical Systems, Inc. (Utah, US) sold as a MeritransTM transducer.
  • Other representative pressure monitors are disclosed in, for example, US patent application number 2005/0004518, incorporated herein by reference.
  • a pressure transducer is integrally mounted in the plunger of a syringe under the plunger tip such that the force applied by the plunger to the fluid in the syringe is transmitted to the transducer and the resulting electronic signal is converted to a display value, aiding the physician in diagnosing diseased disks in the back.
  • the transducer of the pressure monitor can be positioned in the barrel of a syringe or, alternatively, in the connector (or "hub").
  • a dispenser manifold 60 is shown in FIGS. 1 and 2.
  • the dispenser manifold 60 includes dispenser manifold inlet ports 61 , 61' that sealably align and couple with the exit ports 38, 38' of the cartridge 30.
  • the dispenser manifold 60 is adapted to couple to the manifold coupling portion 39 of the cartridge using, for example, fittings 62, 63 that engage complimentary slots 39' so as to lock in the dispenser manifold 60 to the coupling portion 39.
  • the exit ports 38, 38' are embodied within manifold coupling portion 39.
  • the coupling portion 39 may alternatively be formed into the housing 20, though typically is part of the cartridge 30.
  • the dispenser manifold 60 includes fluid tubes 65, 66 that receive and transfer fluid from the cartridge 30 to the needle assembly 80 which is depicted for example in FIGS. 6-9.
  • the tubes 65, 66 can be made of a variety of materials, but in general are made of flexible materials to facilitate improved usage by the surgeon. Typically the tubes 65, 66 are made of polymeric materials, especially medical grade materials. Alternatively, the tubes can be made of soft metals or other materials that permit the tubes to flex.
  • the delivery manifold for delivering the fluids can include a delivery adapter that includes at least two exit ports that each couple to the at least two exit ports of the housing adaptor, at least two conduits having two ends wherein a first end of each of the conduits connects to an exit port of the delivery manifold, and wherein a second end of each of the conduits connects to a duel port luer fittings, wherein the luer fitting is configured to delivery fluid from one conduit to an inner needle and wherein the luer fitting is configured to delivery fluid from the second conduit to a space defined by the exterior of the inner needle and by a second larger diameter needle that connects to the luer fitting with the inner needle being within the insider of the larger diameter needle.
  • FIG. 10 illustrates the device 10 where the manifold 60 has been operably connected to the cartridge 30 so that the inlet ports of the manifold 60 align with the exit ports of the cartridge 30.
  • a fluid fill manifold 90 as depicted in FIG. 11 can be used to load fluids into the cylinders 31 , 31 " of the cartridge 30.
  • the fill manifold 90 includes inlet ports (not shown) that sealably align and couple with exit ports 38, 38".
  • the fill manifold 90 includes fittings 92, 93, and an optional hood 64.
  • the fill manifold 90 includes tubes 95, 96 that couple to syringes 97, 98 that are filled with the fluids to be introduced into the cylinders 31 , 31'.
  • the syringes 97, 98 connect via luer fittings 99, 99' to the tubes.
  • the syringes 97, 98 are filled with fluids (e.g. a thrombin solution and a fibrinogen solution) to be introduced into the cylinders 31 , 31'.
  • fluids e.g. a thrombin solution and a fibrinogen solution
  • the syringes are locked into place using the luer fittings, and then the fluids are injected into the cylinders at which time the plungers 36, 36" are driven back.
  • the fill manifold 90 is removed and replaced with the dispenser manifold 60, which also has fitting to lock the fill manifold in, after which time the surgeon primes the device for use, inserts and locks the inner needle within the outer needle, and injects the biologic sealant of choice into a desired location, such as a disc, in the body.
  • the fill manifold for introducing fluids into the cylinder includes a fill manifold adaptor that couples to the adaptor of the delivery device wherein the adaptor includes at least two exit ports that each couple to the at least two exit ports of the housing adaptor, at least two syringes, at least two conduits wherein one end of the conduit connects to the syringe and a second end of the conduit connects to an exit port of the fill manifold adaptor.
  • the fill manifold 90 can be alternatively connected to a wide variety of refilling parts other than the syringes 97, 98.
  • the fluid fill manifold 90 can use, for example, pressurized containers, automated injection devices, fluid bags that are manually or automatically squeezed to effect refilling into the cylinders, fluid ampoules that are punctured with needles to access the fluids using pressurized gas to force the fluids into the cylinders, and so on.
  • the needle assembly 80 is depicted in FIGS. 6-8.
  • the needle assembly may include two coaxial needles, or an outer needle and an inner polymeric catheter.
  • the outer needle 81 which is inserted directly into the patient to be treated, is connected via luer fittings 82, 82' with the outer needle 81 surrounding an inner needle 82 (see FIG. 7).
  • the outer needle is typically an 18-22 gauge spinal needle that includes a bent portion 81' to assist the surgeon in navigating the body during insertion of the spinal needle.
  • the inner needle can be of any size such that fluids may flow in the gap between the needles.
  • the inner needle 83 may include ports near the tip 83' to facilitate potentially improved mixing of the fluids.
  • FIGS. 9A-9C illustrate cross- sectional views of needles and catheters that may be employed in the practice of this invention. If a multi-lumen catheter or needle is employed, then the luer fitting would be adapted to delivery each fluid to a respective lumen. Referring again to FIGS.
  • the inner needle 83 can be of any length but typically is sized so that when the inner and outer needles are coupled together the tip 83' of the inner needle 83 extends to within between 1 mm and 50 mm of the tip 81 ' of the outer needle 81 , in other embodiments is from about 0.5 inch to about 1.5 inch from the tip of the outer needle, and in one embodiment is from about VA inch to about 1 inch from the distal tip of the outer needle.
  • a fibrinogen solution is provided to the inner needle 83 while a thrombin solution is provided to the outer needle 81. Fluid mixing is initiated at the tip 83' of inner needle 83.
  • FIGS. 9A and 9B show representative cross-sectional views of multi- lumen catheters.
  • FIG. 9A shows a bilumen catheter 200 wherein the lumen are in side-by-side arrangement and in which fibrinogen would be injected through lumen 201 and the activating compound through lumen 202.
  • FIG. 9B a trilumen catheter 210 is depicted wherein a first lumen 211 may carry one fluid, second lumen 212 carries a second fluid, and a third lumen 213 may carry and additive or have a wire inserted through the lumen 213 to improve the physical integrity and rigidity of a polymeric catheter.
  • FIG. 9A shows a bilumen catheter 200 wherein the lumen are in side-by-side arrangement and in which fibrinogen would be injected through lumen 201 and the activating compound through lumen 202.
  • a trilumen catheter 210 is depicted wherein a first lumen 211 may carry one fluid, second lumen 212 carries a second fluid, and
  • FIG. 9C depicts a trilumen catheter 230 wherein the lumen 231 , 232, and 233 are arranged in sequence (in side-by-side relationship).
  • a multi-lumen catheter can be used in this invention.
  • a multi-lumen catheter can have a number of cross-sectional structures.
  • the catheter can also have more than three lumen.
  • FIG. 8 shows a detailed embodiment of the luer fitting 82'.
  • fibrinogen tube 65 feeds fibrinogen solution directly into a port 84 that couples to the inner needle 83.
  • tube 64 feeds thrombin solution, for example, into the hub (the void space) 85 of the luer fitting 82' whereby when the outer needle 81 is connected via luer fitting 82 the thrombin solution flows into the hub and into needle 81. The two fluids do not commingle until one of the solutions exits the inner needle 83.
  • the trigger 40 is depicted in greater detail in FIG. 2.
  • the trigger includes a toothed rack 42.
  • the rack 42 then engages the wheel assembly 50, which rotates as the rack 42 moves backward.
  • the wheel assembly 50 thereby drives rams 34, 34' which move plungers 36, 36' forward toward the exit ports 38, 38'.
  • the trigger is configured such that the teeth of rack 42 engage the teeth of the wheel assembly 50 when pressure is applied to the trigger 40, and configured such that the rack 42 drops away when pressure is released so that the respective teeth no longer engage.
  • This configuration can be provided, for example, by adapting the housing 20 and trigger 40 such that the backward motion of the trigger raises the rack 42 such as, for example, in FIG. 12.
  • the trigger 40 includes a guide bore 44 wherein a guide post 28 attached to the housing glides through the guide bore 44 upon application of pressure to the trigger 40.
  • spring 45 returns the trigger 40 to its original position.
  • a pin 48 that is mounted or integral with the rack 42 slides in the slot 29 to force the rack 42 up or down depending on the angle of the slot 29 to thereby engage the wheel assembly 50 as pressure is applied to the trigger 40.
  • the slot 29 is a part of and integral with the housing 20.
  • the rack 42 may include a slot with a pin being mounted within the housing 20, such that the pin glides in the slot to force the rack 42 to engage the wheel assembly 50.
  • the delivery device of this invention can be used to deliver a wide variety of biologic materials such as but not limited to fibrin sealant, synthetic polymers such as but not limited to polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polyethoxazoline, polyhydroxyethyl acrylate, polyhydroxyethyl methacrylate, polysaccharides, polypeptides, polymers made from polyethylene glycol, materials disclosed in US Patent 6,428,576 (Haldimann) which is incorporated herein by reference, and so on, with or without additives.
  • Fibrin sealant is preferred in the practice of this invention. Fibrin sealant comprises a fibrinogen component and a thrombin component that converts fibrinogen to fibrin.
  • the sealant may contain one or more other components.
  • the fibrin sealant is injected into, for example, the disc to seal fissures and tears in the annulus fibrosus. Defects in the annulus fibrosus are commonly diagnosed, currently, using MRI scans and discograms. This can treat both discogenic low back pain and radiculopathy leg pain when injected into the lumbar intervertebral disc.
  • the fibrinogen used in the practice of this invention includes any fibrinogen that will form fibrin in a human body. Fibrinogen is frequently available in freeze-dried form, and must be reconstituted prior to use. The fibrinogen can also be frozen or fresh.
  • the fibrinogen can be autologous (from the patient to be treated), human including pooled human fibrinogen, recombinant, and bovine or other non-human source such as fish (e.g., salmon and sea trout). The fibrinogen is used in an amount suitable for the given treatment, patient, and so on.
  • the freeze-dried fibrinogen can be reconstituted using, for example, saline, a saline solution containing aprotinin, a saline solution containing calcium chloride, a saline solution containing one or more other additives such as a local anesthetic, or a solution containing combinations of additives.
  • Thrombin is typically the enzyme used which serves to change fibrinogen to fibrin.
  • other enzymes can be used such as those derived from snake venom (e.g., batroxobin), or spider venom as is known in the art.
  • Thrombin is available commercially, typically in its freeze-dried form. Freeze-dried thrombin must be reconstituted prior to use. The thrombin can also be frozen or fresh.
  • Thrombin can be autologous, from a human or pooled human supply, bovine, or other non-human source such as various arachnids and other venomous species. The thrombin is used in any amount which facilitates changing the fibrinogen to fibrin, as is known to one of skill in the art.
  • the thrombin can be reconstituted using saline, a saline solution containing calcium chloride, a saline solution containing one or more other additives such as a local anesthetic, or a solution containing calcium chloride and one or more additives.
  • Additional additives may be added to the fibrin sealant such as, but not limited to: antibiotics; antiproliferative, cytotoxic, and antitumor drugs including chemotherapeutic drugs; analgesic; antiangiogen; antibody; antivirals; cytokines; colony stimulating factors; proteins; chemoattractants; EDTA; histamine; antihistamine; erythropoietin; antifungals; antiparasitic agents; non-corticosteroid anti-inflammatory agents; anticoagulants; anesthetics including local anesthetics such as lidocaine and bupivicaine; analgesics; oncology agents; cardiovascular drugs; vitamins and other nutritional supplements; hormones; glycoproteins; fibronectin; peptides including polypeptides and proteins; interferons; cartilage inducing factors; protease inhibitors; vasoconstrictors, vasodilators, demineralized bone or bone morphogenetic proteins; hormones; lipid
  • any of these additives may be added to the fibrin sealant separately or in combination.
  • One or more of these additives can be injected with the fibrinogen and thrombin, or alternatively one or more of these components can be injected separately, either before or after the fibrin sealant has been injected.
  • an anti-caking agent such as, for example, polysorbate, may be added to facilitate suspension of this component. Glycol may be inappropriate for use as an anti-caking agent in the instant invention.
  • the biologic sealant including fibrinogen and thrombin are injected in amounts effective to seal a given defect of the disc, as is apparent to one of skill in the art.
  • the amount of thrombin can be varied to reduce or lengthen the time to complete fibrin formation. In general, the higher level of thrombin per unit amount of fibrinogen, the faster fibrin formation occurs. If slower fibrin formation is desired, then less thrombin is used per unit fibrinogen.
  • the use of calcium chloride in one or both of the component solutions will affect the strength of the fibrin so formed, with increasing amount of calcium chloride increasing the strength of the fibrin clot.
  • the dosage can range from about 0.05 ml. to about 40 ml_.
  • Fibrin sealants mimic the final stage of the natural clotting mechanism.
  • such sealants entail the mixing of a fibrinogen component with an activating enzyme such as thrombin.
  • thrombin is an enzyme that exists in blood plasma which causes the clotting of blood by converting fibrinogen into fibrin.
  • the components of the fibrin sealant are reconstituted separately, from a freeze-dried state, prior to use. However, the use of samples prepared from a frozen state or a fresh state is also acceptable.
  • various components may be supplied endogenously from host body fluids. Combining the reconstituted components produces a viscous solution that quickly sets into an elastic coagulum.
  • a method of preparing a conventional fibrin sealant is described by J. Rousou, et al. in Journal of Thoracic and Cardiovascular Surgery, vol. 97, no. 2, pp 194-203, Feb. 1989.
  • Cryoprecipitate derived from source plasma is washed, dissolved in buffer solution, filtered and freeze-dried.
  • the freeze-dried fibrinogen is reconstituted in a fibrinolysis inhibitor solution containing, for example 3000 KILJ/ml of aprotinin (a polyvalent protease inhibitor which prevents premature degradation of the formed fibrin).
  • the solution is stirred and heated to a temperature of about 37 0 C.
  • Each solution (the thrombin and fibrinogen solutions) is drawn up in a dual barrel syringe and mounted on a Y-connector to which a needle is attached for delivery of the combined solution.
  • a needle is attached for delivery of the combined solution.
  • fibrin formation begins immediately on contact of the fibrinogen and thrombin.
  • injecting of fibrin sealant or other biologic sealant thus encompasses any injection of components that form sealant in the disc, including circumstances where a portion of the components react to form sealant due to mixing prior to contact with or actual introduction into the disc (i.e., within the needle assembly).
  • the point, or points, of injection can be within the annulus fibrosus or in the nucleus pulposus. If the injection occurs in the nucleus pulposus, the injected components may form a patch at the interface between the nucleus pulposus and the annulus fibrosus, or, more commonly, the components flow into the defect(s) (e.g., fissures) of the annulus fibrosus and potentially "overflowing" into the interdiscal space. In practice, over-pressurizing the disc by injecting the components into the disc should be avoided.
  • freeze-dried fibrinogen is reconstituted according to conventional methods, and about 45-55 mg/mL thrombin component is reconstituted separately from a freeze-dried state according to the methods and compositions of the present invention.
  • Freeze- dried fibrinogen and freeze-dried thrombin are available in kit-form from such manufacturers as Baxter under names such as TISEEL®. These two fibrin sealant components can be prepared for example in about 2ml_ samples each to yield approximately 4ml_ of total sealant (reconstituted fibrinogen plus reconstituted thrombin).
  • one method is providing about 45-55 mg/mL of freeze-dried thrombin and mixing it with a reconstituting solution.
  • the reconstituting solution may optionally further comprise about 0.1-100 milligrams of another additive described herein (e.g., local anesthetic) and/or calcium chloride.
  • the calcium chloride concentration can be, for example, 1-100 millimoles/mL, and in one embodiment 4-40 millimoles/mL. If employed, the calcium chloride concentration should be sufficient to further the polymerization reaction that forms a durable fibrin sealant clot.
  • a preservative-free reconstituting solution may be desirable, but is not required.
  • a contrast agent may be used in conjunction with the injection of the fibrin sealant.
  • the contrast agent may be injected prior to injection of the fibrin sealant.
  • the contrast agent is included in the fibrinogen component or thrombin component that is injected into the disc. Contrast agents and their use are well known to one of skill in the art.
  • fibrinogen and thrombin may be used to form the desired fibrin sealant clot in the body.
  • varying the fibrinogen and/or thrombin amount/concentration may be done to vary the viscosity and the "setting time" of the combined fibrinogen and thrombin components.
  • varying fibrinogen may change the density of the combined components, which may be important for controlling flow through a long conduit such as a catheter into the body.
  • Varying thrombin may vary the polymerization time of the components, which may be important for controlling the time at which the clot forms for ensuring the components set-up at the proper site and time in the body rather than setting-up prematurely.
  • the thrombin reconstituting solution e.g., a saline based solution
  • the thrombin reconstituting solution can be prepared in a single vial prior to mixing with the freeze-dried thrombin.
  • This component of the fibrin sealant may then be provided to users in a reconstituted state, or in two uncombined vials containing freeze-dried thrombin and a premixed reconstitution solution. Mixing of the contents of the two vials may be performed at any point up to, and including, the time at which the fibrin sealant is injected into the patient.
  • the fibrinogen component may be reconstituted in an aprotinin saline solution which optionally contains additives such as, for example, a local anesthetic.
  • the thrombin or the fibrinogen or both can be reconstituted using a saline solution that contains one or more additives. All solutions are brought to a temperature of about 37°C.
  • the thrombin is combined with the fibrinogen solution using the dual-syringe injection procedure described herein to form a single sealant composition which is injected into a patient.
  • the instant invention provides a vehicle for the delivery of the sealant that conveys the sealant to the precise area of the back, seals any annular fissures, and holds the fibrin in place via the elastic coagulum.
  • the biodegradable nature of the formed fibrin clot minimizes or eliminates the need for invasive surgical removal following the effective period of use. Therefore, an advantage of the sealant and method of application is the ability to provide a minimally invasive means of accomplishing localized, prolonged sealing of defects (e.g., fissures) in the annulus fibrosus, and if an additive is in the sealant, time-released additive delivery.
  • the fibrin sealant may be injected into the disc or other body area using procedures well known to one of skill in the art.
  • the fibrin sealant of this invention is injected into the disc, the epidural space, the zygaphysical (2-joint) joint, the vertebral canal, and/or thecal sac.
  • an injection of fibrin sealant into a disc serves to create a fibrin matrix which seals the disc from leaking material from the nucleus into the area outside the disc.
  • the fibrin sealant can be delivered by fluoroscopic transforaminal lumber epidural or intra-discal injection, such as described in U.S. 6,468,527, incorporated herein by reference.
  • the fibrin sealant is injected into the nucleus pulposus to fill any fissures or voids of the annulus fibrosus, to seal the bone end plates to the disc, increase pressure of the disc, and to increase the height of the disc space.
  • the injection may also serve to coat areas adjacent to the disc, directly on the nerve roots and surrounding areas which serve to protect those areas from the effects of the leaking nucleus material. Sealing the fissures and bone end plates halts the leakage of harmful chemicals into the disc environment and prevents the initiation of foreign-body reactions towards the damaged disc by the immune system. Increasing the disc space relieves pressure from the nerve root.
  • Example 1 FLUOROSCOPIC TRANSFORAMINAL EPIDURAL INJECTION
  • a fluoroscope is positioned and adjusted to locate the intervertebral foramen of the affected nerve root.
  • a curved 22ga. X 3.5" needle is introduced after anesthetizing the skin and deep tissue.
  • the needle is advanced under direct fluoroscopic vision to a position in the anterior epidural space. Positioning of the needle is verified by a lateral fluoroscopic view and by injecting contrast medium through the needle. Such positioning may or may not require further adjustment. If adjusted, location of the needle is once again verified. Advancement of the needle into the correct region may stimulate pain in a manner consistent with the initial complaint. Therefore, needle placement may also be verified by the patient's pain recognition.
  • the epidural space is anesthetized with injectable anesthetic.
  • the fibrin sealant of fibrinogen and thrombin (prior to clotting) is then introduced using the device of this invention such as shown in the FIGS, until the volumes of the dual syringe system are sufficiently depleted. The fibrin sealant then coats the nerve root and annulus and the needle is withdrawn. Patient observation and vital signs monitoring is performed for about 20-30 minutes following the procedure.
  • the fibrin sealant is injected to effectively hydro-dissect the area around the targeted nerve root. It is believed that due to the avascular nature of the epidural space, the absorption/degradation period is typically longer than that observed for open applications in regions with greater vascularity and exposure to room air at the time of application.
  • the ability of the fibrin sealant to seal annular fissures related to disc herniation offers a therapeutic benefit to patients.
  • Chemical radiculitis, or inflammation of the nerve root is known to be quite painful in some instances. It is believed that use of the fibrin sealant in the above described manner not only coats the nerve root, but also seals annular fissures surrounding the herniated disk. As a result of the hydro-dissection of the area around the affected nerve root, the sealant also seals annular fissures from outside the annulus.
  • an introducer needle is advanced in oblique projection to a superior articular process.
  • a curved spinal needle is advanced through the introducer needle into the disc.
  • Both anterior-posterior and lateral fluoroscopic projections are used to confirm proper needle placement. If the needle placement needs to be adjusted, placement is again confirmed fluoroscopically.
  • a contrast agent is injected to confirm needle placement. In patients with chemical radiculitis, the contrast agent can be observed to be leaking through the annular fissures and/or intra-discal pathology can be identified.
  • the fibrin sealant is injected using the delivery device of this invention such as shown in the FIGS.
  • the fibrin sealant is observed to force the contrast agent from the intra-discal space as it seals the annual fissures.
  • the contrast agent is injected with the sealant.
  • no contrast agent is used. The procedure seals the defects/fissures of the annulus fibrosus and stops the chemical leakage and facilitates regeneration within the disc.
  • TISSEEL VH S/D fibrin sealant was prepared according to manufacturer guidelines. The reactive components were mixed and delivered using a DUPLOJECT delivery device or the deliver device of this invention as shown in FIGS. 1-8 and 9-12.
  • the tip of the inner needle was approximately one inch short of the distal tip of the introducer needle.
  • the inner needle was a 22 gauge needle and the outer needle was an 18 gauge needle.
  • Biostat refers to the device used in the tests constructed according to this invention.
  • a DUPLOJECT delivery device is the standard device used currently for mixing and providing fibrin sealant.
  • the DUPLOJECT device includes dual syringes that feed fibrinogen solution and thrombin solution into a Y- connector where mixing of the solutions is initiated.
  • the DUPLOJECT device is equipped with a standard one inch length 18 gauge needle, which is the needle provided with the DUPLOJECT delivery device.
  • solutions are placed in two syringes, the syringes are loaded into the dual syringe clip of the DUPLOJECT device, the mixing chamber is attached to the tips of the syringes and fastened to the dual syringe clip using the retaining strap, and the needle is then attached to the mixing chamber.
  • the DUPLOJECT delivery device has been approved for use with fibrin sealant by the US Food and Drug Administration, and is mentioned in US Patent 6,468,527 for use in injecting fibrin sealant and corticosteroid into a disc.
  • Identical fibrinogen and thrombin solutions (TISSEEL fibrin sealant components using 500 IU/mL thrombin) were loaded into in each device. The solutions were then pushed through the devices so that fibrin sealant was injected from each device. A total of eight clots were cast from four batches of sealant for each delivery device. Controlled sample volumes (1.6 mL) were delivered by extrusion into controlled diameter test tubes (12 x 75 mm). This sample preparation protocol was designed to ensure the formation of a level, planar test surface with homogenous product distribution and controlled surface area and sample height. The test tubes were sealed and stored in a 37 degree Centigrade water bath for 90 minutes to allow complete product curing prior to mechanical testing. The mechanical properties of the resulting clots were measured, including failure load, elastic stiffness, and failure deformation. Material toughness was also estimated by calculating the area under the load-deformation curves.
  • a calibrated Texture Analyzer XT was used as a multifunction tensiometer to measure the forces generated during the controlled depression (2 mm/min, 10 mm maximum displacement) of a % inch cylindrical probe into the surface of the clot. Compression of the gel yielded a steady linear rise in load until failure, demonstrated graphically by an abrupt deviation from linearity.
  • failure force refers to the force measured at the moment of the deviation from linearity.
  • Failure displacement refers to the distance traveled by the probe until the moment of deviation, with failure deformation providing an estimate of the clot ductility.
  • Elastic stiffness refers to the change in force over change in time (slope) of the linear portion of the load-deformation graph just preceding failure. Elastic stiffness provides and assessment of the clot's resistance to deformation, with higher values representing stiffer materials.
  • Table 1 provides the results of the mechanical testing of fibrin sealant clots produced by the DUPLOJECT device and the device according to this invention.
  • the DUPLOJECT device and the Biostat device produced clots with average elastic stiffness loads of 235 g/mm (+/- 61 ) and 107 g/mm (+/- 42), respectively.
  • the clots produced from the Biostat device were reduced in elastic stiffness by 54% relative to the DUPLOJECT device.
  • the DUPLOJECT device and the Biostat device produced clots that failed after an average deformation of 2.64 mm (+/- 0.35) and 6.56 mm (+/- 1.65) respectively.
  • the DUPLOJECT device and the Biostat device produced clots with an average material toughness proportional to 269.8 g-mm (+/- 50.7) and 543.5 g-mm (+/- 244.6, respectively.
  • the clots produced from the Biostat device could absorb twice as much energy (+101.5%) prior to catastrophic failure relative to the clots produced by the DUPLOJECT device.
  • Viscometry profiles were also determined. The procedures above were used to prepare clots from the DUPLOJECT device and Biostat device. Reheometric Scientific's SR5 Controlled Stress Rheometer was used to measure the rheological properties of the setting fibrin clots at body temperature. A cone and plate geometric configuration (d ⁇ 25mm, 4°) was used for viscosity profile assessment. Standardized test protocols were utilized. Shear rates ranging from 0.1 to 80 sec "1 were used. In the dynamic experiments, an oscillatory shear was applied to the samples while the corresponding elastic (G') and viscous (G”) moduli were measured as a function of frequency. Samples were assessed using frequency ranges from 0.01 rad/s to 100 rad/s.
  • working time refers to the duration required for the fibrin solution viscosity to reach 750 poise. At this viscosity, the pressure required for syringe delivery exceeds a 15 psi threshold for hand delivery. The working time limit represents the period of time the physician has to deliver the entire product to the disc.
  • the data shows that the Biostat device increases working time significantly and provides significantly improved control for intradiscal delivery. In addition, the Biostat device provides fibrin sealant that allows for slow delivery and maximizes the potential for low viscosity components to permeate into annular disruptions (fissures).
  • the Biostat device surprisingly increases work time to 1.75 minute (+/- 0.73), an 134% average improvement over fibrin sealant made using the DUPLOJECT device which had a work time of 0.65 min (+/- 0.02).
  • the results are shown in FIG. 13.
  • FIG. 13 it can be seen that the fibrin sealant delivered from a DUPLOJECT device sets up significantly faster than fibrin sealant delivered from a Biostat device.
  • the setting or solidification time was arbitrarily defined as the duration required for the fibrin solution viscosity to reach 10,000 poise (roughly equivalent to solid vegetable shortening).
  • the results show that the Biostat device significantly and surprisingly increased the set time to 5.77 min (+/- 1.76) from the 2.90 min (+/-0.38) from the DUPLOJECT device. This provides a distinct advantage for the practitioner by allowing the fibrin to more fully infiltrate annular fissures and so on, and associated significant performance benefits for intradiscal injection of a biologic sealant. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un dispositif permettant d'administrer des substances biologiques qui comprend : une cartouche comportant au moins deux alésages de cylindres pour les fluides à administrer, dans lequel chaque cylindre inclut un orifice d'entrée pour un fluide, un plongeur à l'intérieur de chaque cylindre pour expulser les fluides hors du cylindre, un boîtier adapté pour recevoir la cartouche, dans lequel le boîtier ou la cartouche inclut un adaptateur destiné à recevoir et verrouiller un collecteur qui se branche de manière opérationnelle aux orifices de sortie de la cartouche, au moins deux pistons dentés, dans lequel chaque piston denté se situe au moins en partie à l'intérieur d'un alésage de cylindre, une gâchette reliée au boîtier, dans lequel la gâchette inclut une crémaillère d'entraînement dentée, un assemblage à roue dentée qui collabore avec la crémaillère d'entraînement dentée et avec les pistons dentés, et aussi des procédés de fabrication du dispositif, des procédés d'utilisation du dispositif pour traiter des disques, des kits incluant le dispositif.
PCT/US2007/022533 2006-10-24 2007-10-24 Appareil et proceédeé permettant d'administrer un agent d'etancheéiteé biologique WO2008051561A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85441306P 2006-10-24 2006-10-24
US60/854,413 2006-10-24

Publications (2)

Publication Number Publication Date
WO2008051561A2 true WO2008051561A2 (fr) 2008-05-02
WO2008051561A3 WO2008051561A3 (fr) 2008-08-21

Family

ID=39325175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022533 WO2008051561A2 (fr) 2006-10-24 2007-10-24 Appareil et proceédeé permettant d'administrer un agent d'etancheéiteé biologique

Country Status (1)

Country Link
WO (1) WO2008051561A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103245A1 (fr) * 2010-02-19 2011-08-25 Cook Medical Technologies Llc Appareil et méthode de dissection sous-muqueuse par voie endoscopique
WO2019118588A1 (fr) * 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Dispositifs et procédés d'administration de doses de précision
US11439758B2 (en) 2019-06-05 2022-09-13 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11452798B2 (en) 2017-09-27 2022-09-27 Cook Medical Technologies Llc Crosslinking submucosal injectate system
WO2023096630A1 (fr) * 2021-11-23 2023-06-01 Bard Peripheral Vascular, Inc. Dispositifs, systèmes et procédés pour l'administration d'écarteurs multi-composants et de solutions d'hydro-dissection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132396A (en) * 1996-02-06 2000-10-17 Plasmaseal Llc Apparatus for applying tissue sealant
US6387977B1 (en) * 1995-03-23 2002-05-14 Focal, Inc. Redox and photoinitiator systems for priming for improved adherence of gels to substrates
US6599272B1 (en) * 1999-05-12 2003-07-29 Pharmacia Ab Injection device and method for its operation
US20060106364A1 (en) * 2004-10-29 2006-05-18 Whitlock Steven I Injection of fibrin sealant in the absence of corticosteroids in spinal applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387977B1 (en) * 1995-03-23 2002-05-14 Focal, Inc. Redox and photoinitiator systems for priming for improved adherence of gels to substrates
US6132396A (en) * 1996-02-06 2000-10-17 Plasmaseal Llc Apparatus for applying tissue sealant
US6599272B1 (en) * 1999-05-12 2003-07-29 Pharmacia Ab Injection device and method for its operation
US20060106364A1 (en) * 2004-10-29 2006-05-18 Whitlock Steven I Injection of fibrin sealant in the absence of corticosteroids in spinal applications

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103245A1 (fr) * 2010-02-19 2011-08-25 Cook Medical Technologies Llc Appareil et méthode de dissection sous-muqueuse par voie endoscopique
AU2011218128B2 (en) * 2010-02-19 2014-08-07 Cook Medical Technologies Llc Apparatus and method for endoscopic submucosal dissection
US11452798B2 (en) 2017-09-27 2022-09-27 Cook Medical Technologies Llc Crosslinking submucosal injectate system
WO2019118588A1 (fr) * 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Dispositifs et procédés d'administration de doses de précision
KR20200098588A (ko) * 2017-12-13 2020-08-20 리제너론 파아마슈티컬스, 인크. 정밀 도즈 전달을 위한 장치 및 방법
US11433186B2 (en) 2017-12-13 2022-09-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
KR102602601B1 (ko) 2017-12-13 2023-11-16 리제너론 파아마슈티컬스, 인크. 정밀 도즈 전달을 위한 장치 및 방법
US11439758B2 (en) 2019-06-05 2022-09-13 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
WO2023096630A1 (fr) * 2021-11-23 2023-06-01 Bard Peripheral Vascular, Inc. Dispositifs, systèmes et procédés pour l'administration d'écarteurs multi-composants et de solutions d'hydro-dissection

Also Published As

Publication number Publication date
WO2008051561A3 (fr) 2008-08-21

Similar Documents

Publication Publication Date Title
US8047407B2 (en) Apparatus and method for delivery of biologic sealant
US8419722B2 (en) Apparatus and method for injection of fibrin sealant in spinal applications
US20070213660A1 (en) Fibrin sealant delivery device including pressure monitoring, and method and kits thereof
US8403923B2 (en) Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US8357147B2 (en) Method for repairing intervertebral discs
US8206448B2 (en) Injection of fibrin sealant using reconstituted components in spinal applications
US8403895B2 (en) Injection of fibrin sealant including an anesthetic in spinal applications
WO2008150354A1 (fr) Procédé, composition et kit pour traiter une maladie de dégénérescence de disque et une douleur d'origine discale
AU2011210817A1 (en) An injection shut off valve with pressure actuator for delivery of compositions
WO2008051561A2 (fr) Appareil et proceédeé permettant d'administrer un agent d'etancheéiteé biologique
US9433436B2 (en) Therapeutic material delivery system for tissue voids and cannulated implants
CN101400325A (zh) 包括压力监视的纤维蛋白密封剂递送装置和方法及其器械包
US20130261597A1 (en) Therapeutic Material Delivery System for Tissue Voids and Cannulated Implants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861495

Country of ref document: EP

Kind code of ref document: A2